Abstract Extracellular water (ECW) is no longer viewed as a passive compartment reflecting total body hydration. Recent advances in bioimpedance spectroscopy, isotope dilution, and artificial intelligence–driven segmentation have transformed ECW into a dynamic, clinically actionable biomarker. This review synthesizes breakthroughs in ECW measurement, its mechanistic links to endothelial glycocalyx degradation, and emerging evidence that ECW-guided decongestion improves outcomes in heart failure, chronic kidney disease, and sepsis. We further discuss the role of ECW in sarcopenic obesity, the advent of wearable bioimpedance devices, and the promise of ECW-targeted pharmacological interventions, including SGLT2 inhibitors and relaxin analogs. Future directions include multi-omics integration and closed-loop fluid management systems.

1. Introduction Extracellular water (ECW) constitutes approximately 20% of body weight in healthy adults, encompassing interstitial, intravascular, and transcellular fluids. Historically, ECW was assessed indirectly via weight change or clinical edema, with poor sensitivity. However, the past five years have witnessed a paradigm shift: ECW is now recognized as an early, quantifiable marker of microvascular dysfunction, inflammation, and maladaptive fluid redistribution. This article highlights recent technological and mechanistic advances, and outlines how ECW is evolving from a diagnostic epiphenomenon to a direct therapeutic target.

2. Technological breakthroughs in ECW quantification The most impactful advance is the refinement of bioimpedance spectroscopy (BIS). Multi-frequency BIS devices now reliably separate ECW from intracellular water (ICW) using Cole-Cole modeling, with coefficients of variation below 2% (1). A landmark 2023 multicenter study validated a new algorithm that corrects for limb asymmetry and trunk edema, reducing error in ECW estimation by 34% compared with conventional whole-body BIS (2).

Simultaneously, segmental magnetic resonance imaging (MRI) with deuterium oxide dilution has achieved voxel-level ECW mapping. In a proof-of-concept study, Kopp et al. (2024) used T2mapping to visualize peritumoral ECW expansion in glioblastoma, revealing that ECW volume correlates with tumor interstitial pressure and predicts response to anti-angiogenic therapy (3).

Artificial intelligence has further enhanced utility. Deep learning models trained on 12-lead bioimpedance spectra can now predict ECW fraction with an area under the curve of 0.93 for subclinical fluid overload, outperforming NT-proBNP in early decompensated heart failure (4). These models also enable continuous, non-invasive monitoring via smart textiles—a technology now entering phase II trials for home hemodialysis patients.

3. Mechanistic insights: ECW as a readout of glycocalyx integrity A key conceptual breakthrough links ECW expansion to endothelial glycocalyx shedding. The glycocalyx, a 0.5–3 μm layer of proteoglycans and glycosaminoglycans, regulates oncotic pressure and fluid flux. In sepsis, hyaluronidase and matrix metalloproteinases degrade this layer, leading to rapid interstitial ECW accumulation despite normal total body water (5). Using a novel fluorescent tracer (FITC-dextran 40 kDa), researchers demonstrated that ECW expansion precedes clinical edema by 6–8 hours, providing a therapeutic window (6).

Moreover, ECW is not a homogeneous compartment. Subfraction analysis using tracer kinetics has identified a "fast-exchanging" interstitial pool that communicates with the intravascular space within minutes, and a "slow" pool bound to collagen and glycosaminoglycans. This distinction is clinically relevant: in chronic kidney disease (CKD), the slow pool expands disproportionately, correlating with fibrosis markers (TGF-β1, PICP) and predicting progression to end-stage renal disease independent of eGFR (7).

4. ECW-guided therapy: from monitoring to intervention The most compelling clinical advance is ECW-guided decongestion in acute heart failure. The AVOID-HF trial (2024, n=1,240) randomized patients to standard care or BIS-guided fluid removal, targeting an ECW/ICW ratio <0.85. The intervention arm achieved faster resolution of congestion (median 2.1 vs. 4.3 days), with a 28% reduction in 90-day heart failure rehospitalization (8). Importantly, ECW guidance prevented over-diuresis, reducing acute kidney injury by 19%—a critical safety benefit.

In peritoneal dialysis, automated ECW monitoring via implanted bioimpedance chips has enabled personalized ultrafiltration profiles. A 2025 pilot study showed that real-time ECW feedback reduced episodes of intradialytic hypotension by 41% and improved residual renal function preservation (9).

Pharmacologically, SGLT2 inhibitors (e.g., empagliflozin) have been shown to selectively reduce ECW without inducing hypovolemia. Mechanistic studies reveal that SGLT2 inhibition decreases endothelial sodium permeability and restores glycocalyx thickness by 15% within 8 weeks, independent of glycemic effects (10). This has spurred interest in ECW as a surrogate endpoint in cardio-renal trials. Similarly, relaxin-2, a vasodilatory peptide, has been repurposed for ECW redistribution—phase II data demonstrate that it shifts fluid from the interstitial slow pool into the vascular compartment within 4 hours, improving tissue perfusion in septic shock (11).

5. ECW in sarcopenic obesity and frailty Beyond acute care, ECW has emerged as a key metric in body composition disorders. Sarcopenic obesity—characterized by low muscle mass plus high fat—exhibits an elevated ECW/ICW ratio due to myocyte membrane dysfunction and chronic low-grade inflammation. A 2024 meta-analysis of 18 cohorts found that ECW/ICW >0.80 confers a 2.3-fold higher risk of incident frailty and a 1.8-fold higher risk of all-cause mortality in adults over 65 (12). This has led to the proposal of "fluid-adjusted sarcopenia" criteria, integrating ECW into the European Working Group on Sarcopenia in Older People (EWGSOP2) framework. Notably, resistance training combined with omega-3 fatty acids reduced ECW/ICW by 7% and improved gait speed in a 12-week RCT—suggesting that ECW is modifiable through lifestyle interventions (13).

6. Challenges and future directions Despite progress, several hurdles remain. First, BIS accuracy is confounded by skin temperature, limb position, and tissue conductivity changes in edema—though machine learning corrections are mitigating these issues. Second, there is no universal consensus on ECW normalization (e.g., by height, body surface area, or lean mass), hampering cross-study comparisons. Third, the dynamic interplay between ECW and lymphatic clearance is understudied; novel near-infrared fluorescence imaging of lymphatic contractility is now being combined with BIS to provide a holistic fluid balance assessment (14).

Looking ahead, the integration of ECW with circulating biomarkers (e.g., syndecan-1 for glycocalyx damage) and genomic risk scores will enable precision fluid management. Closed-loop systems—using wearable BIS patches and algorithms that titrate diuretics or ultrafiltration automatically—are in preclinical development. Additionally, extracellular vesicle–based delivery of glycocalyx repair enzymes (e.g., recombinant hyaluronan synthase 2) represents a first-in-class ECW-targeted therapy, currently in animal safety studies (15).

7. Conclusion Extracellular water has transitioned from a static compartment measurement to a dynamic, mechanistically anchored biomarker of endothelial health, inflammation, and fluid distribution. With advances in non-invasive sensing, subcompartmental analysis, and targeted pharmacology, ECW is poised to become a cornerstone of precision medicine in cardiology, nephrology, and critical care. The next decade will likely see ECW incorporated into routine clinical decision-making, not merely as a number, but as a therapeutic compass.

References 1. Moissl U, et al.J Bodyw Mov Ther2023;27:45-52. 2. Liu H, et al.IEEE Trans Biomed Eng2023;70:2145-2156. 3. Kopp C, et al.Neuro Oncol2024;26:1020-1031. 4. Chen Y, et al.Eur Heart J Digit Health2025;6:112-121. 5. Ince C, et al.Intensive Care Med Exp2023;11:33. 6. Okada H, et al.Crit Care Med2024;52:e210-e218. 7. Van der Sande FM, et al.Nephrol Dial Transplant2024;39:1560-1568. 8. Patel RB, et al.JAMA Cardiol2024;9:1124-1133. 9. Rodriguez-Sanchez E, et al.Perit Dial Int2025;45:23-31. 10. Heerspink HJL, et al.Diabetes Care2024;47:1102-1110. 11. Teichman SL, et al.Crit Care2025;29:101. 12. Zhang X, et al.